INHIBITEX REPORTS DATA FROM AUREXIS TRIAL

Inhibitex has announced results of a Phase II clinical trial evaluating Aurexis as a first-line therapy, in combination with standard of care antibiotics, for serious, life-threatening Staphylococcus aureus bloodstream infections. The study was primarily a test of safety and pharmacokinetics, but also represented an initial step in assessing the potential of Aurexis to improve cure rates over current standard of care therapy.

Sixty patients with both hospital-associated and community-acquired staph bloodstream infections were included in the trial. Positive trends were observed in the composite primary endpoint of mortality, relapse rate and infection-related complications, and a number of secondary endpoints, including the progression in the severity of sepsis and days in the intensive care unit.